department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

POMALIDOMIDE · pharmadog

pharmadog
drugs
POMALIDOMIDE

drug

patient view →

POMALIDOMIDE

Marketedupdated 2mo ago

by Celgene Corp

Approved

community read0 votes

all catalysts(5)

approval · 5

POMALIDOMIDE — FDA approval

POMALIDOMIDE — FDA approval

POMALIDOMIDE — FDA approval

POMALIDOMIDE — FDA approval

POMALIDOMIDE — FDA approval

News(0)

no news has mentioned this drug yet

brand

POMALIDOMIDE

generic

POMALIDOMIDE

indication

Kaposi Sarcoma

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov

last refreshed 46m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 30, 2026

54 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (24)

Dec 21, 2031patentUS 8828427*PED
Dec 21, 2031patentUS 8828427*PED
Dec 21, 2031patentUS 8828427*PED
Dec 21, 2031patentUS 8828427*PED
Jun 21, 2031compositionUS 88284275.0y
Jun 21, 2031compositionUS 88284275.0y
Jun 21, 2031compositionUS 88284275.0y
Jun 21, 2031compositionUS 88284275.0y
Nov 19, 2030patentUS 10555939*PED4.4y
Nov 19, 2030patentUS 10555939*PED4.4y
Nov 19, 2030patentUS 10555939*PED4.4y
Nov 19, 2030patentUS 10555939*PED4.4y
Nov 19, 2030patentUS 9993467*PED4.4y
Nov 19, 2030patentUS 9993467*PED4.4y
Nov 19, 2030patentUS 9993467*PED4.4y
Nov 19, 2030patentUS 9993467*PED4.4y
May 19, 2030formulationUS 105559393.9y
May 19, 2030formulationUS 105559393.9y
May 19, 2030formulationUS 105559393.9y
May 19, 2030formulationUS 105559393.9y
May 19, 2030formulationUS 99934673.9y
May 19, 2030formulationUS 99934673.9y
May 19, 2030formulationUS 99934673.9y
May 19, 2030formulationUS 99934673.9y

FDA exclusivities (16)

Nov 14, 2027PEDPediatric (6mo bonus)1.4y
Nov 14, 2027PEDPediatric (6mo bonus)1.4y
Nov 14, 2027PEDPediatric (6mo bonus)1.4y
Nov 14, 2027PEDPediatric (6mo bonus)1.4y
May 14, 2027ODE-296Orphan Drug (7y)311d
May 14, 2027ODE-297Orphan Drug (7y)311d

🐶 often sniffed alongside

top 3

tagApproval16 co-mentions · 8 sources
tagSmall Molecule8 co-mentions · 8 sources
companyHetero Labs Ltd2 co-mentions · 2 sources

May 14, 2027ODE-296Orphan Drug (7y)311d

May 14, 2027ODE-297Orphan Drug (7y)311d

May 14, 2027ODE-296Orphan Drug (7y)311d

May 14, 2027ODE-297Orphan Drug (7y)311d

May 14, 2027ODE-296Orphan Drug (7y)311d

May 14, 2027ODE-297Orphan Drug (7y)311d

Aug 30, 2026PCPC54d

Aug 30, 2026PCPC54d

Aug 30, 2026PCPC54d

Aug 30, 2026PCPC54d

Trials studying POMALIDOMIDE

phase1A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myelomaactive not recruitingn=140
phase1A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myelomaactive not recruitingn=166
phase2Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosisrecruitingn=53
phase3MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)recruitingn=492
phase2Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Settingcompletedn=186
phase3All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelomaactive not recruitingn=21
phase3A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)recruitingn=810
phase1A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myelomarecruitingn=165

more trials →